关键信息
-
基因名
NAP-2/CXCL7
-
简介
CXCL7 (also known as neutrophil activating peptide 2, NAP-2) is a platelet-derived growth factor that belongs to the ELR+ CXC chemokine family, functioning as a potent chemoattractant and activator of neutrophils through binding to its receptor CXCR2[1]. NAP-2/CXCL7 Protein, Human (HEK 293, His) is produced in HEK293 cells with six C-Terminal His-tags. It consists of 94 amino acids (S35-D128).
- 应用
-
别名
C-X-C motif chemokine 7; PBP; LDGF; MDGF; CTAP-III; PPBP; NAP-2; CXCL7
-
种属
Human
-
表达系统
HEK293
-
标签
C-6*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P02775
-
表达区间
S35-D128
-
蛋白长度
Full Length of Mature Protein
-
分子量
12-16 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
NAP-2, also known as CXCL7, is a member of the CXC chemokine family and plays a crucial role in immune responses and inflammation. This chemokine is primarily produced by platelets and various immune cells, where it functions as a potent chemotactic factor, attracting neutrophils and other inflammatory cells to sites of injury or infection. Recent studies have highlighted its involvement in various pathological conditions, including cancer, atherosclerosis, and autoimmune diseases, suggesting that NAP-2/CXCL7 could serve as both a biomarker and a therapeutic target. Due to its significant role in modulating immune cell activity, researchers have focused on the production and characterization of recombinant NAP-2/CXCL7 protein to further understand its biological functions and mechanisms. Recombining this protein allows for the exploration of its effects on cell signaling pathways, migration, and activation of immune responses. Additionally, developing recombinant NAP-2/CXCL7 can facilitate high-throughput drug screening and the discovery of novel therapeutic agents aiming to modulate its activity for potential clinical applications. Overall, this research background highlights the importance of NAP-2/CXCL7 in both basic and translational immunology, paving the way for future studies that could lead to new treatments for inflammation-related disorders.
